Quotient Limited (QTNT) Return on Equity ROE from the third quarter 2023 to third quarter 2021 and annually, average high and low, overall ranking from Dec 31 2022 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Quotient Limited  (NASDAQ: QTNT)

Quotient Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Quotient Limited in the third quarter 2023?
Due to the lack of equity, it was not possible to calculate Quotient Limited's return on equity (ROE) in its third quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2022)
III. Quarter		 (Sep 30 2022)
II. Quarter		 (Jun 30 2022)
I. Quarter		 (Mar 31 2022)
IV. Quarter		 (Dec 31 2021)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -124 -156 -137 -125 -140
Return On Equity (TTM) - - - - -
QTNT's Total Ranking # # # # #
Equity (TTM) in Millions -209 -182 -151 -144 -126
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to QTNT Management Effectiveness >> QTNT's 5 Years Annual ROE >> Compare QTNT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





QTNT Annual Return On Equity (Mar 31 2022)
2022		 (Mar 31 2021)
2021		 (Mar 31 2020)
2020		 (Mar 31 2019)
2019		 (Mar 31 2018)
2018
Total Equity in Millions -144 -36 -6 2 -15
Y / Y Equity Change - - - - -
Net Income in Millions -125 -111 -103 -105 -82
Y / Y Net Income Change - - - - -
Return On Equity - - - -6148.54 % -

Back to QTNT Management Effectiveness >> QTNT's 5 Years Annual ROE >> Compare QTNT ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
QTNT's' Return on Equity at Yahoo Finance
QTNT's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for QTNT's Competitors
Subscribers only: Roe for Quotient Limited's Suppliers
Subscribers only: Return On Equity for QTNT's Customers




Companies with similar Return On Equity at Dec 31 2022, within Healthcare Sector ROE
Waters Corporation  172.72 %
Ir med Inc   162.82 %
Gsk Plc  154.72 %
Galmed Pharmaceuticals Ltd   133.35 %
Gyre Therapeutics Inc   125.46 %
Idexx Laboratories Inc  124.52 %
Chimerix Inc   113.54 %
Halozyme Therapeutics Inc   98.57 %
Biomx Inc  94.11 %
Davita Inc   92.73 %
Vaso Corporation  80.20 %
Opus Genetics Inc   79.52 %
Abbvie Inc   73.67 %
Assertio Holdings inc   72.98 %
Kiniksa Pharmaceuticals International Plc  66.68 %
Novo Nordisk A  65.46 %
Tff Pharmaceuticals Inc  65.46 %
Dynavax Technologies Corporation  65.38 %
Dariohealth Corp   64.99 %
Avid Bioservices Inc   64.65 %
Eli Lilly And Company  63.95 %
Aptevo Therapeutics Inc   63.08 %
Maravai Lifesciences Holdings Inc   61.82 %
Medpace Holdings Inc   60.42 %
Harmony Biosciences Holdings inc   60.10 %
Shockwave Medical Inc   59.99 %
Sensus Healthcare Inc   53.08 %
Molecular Partners Ag  50.11 %
Biontech Se  47.04 %
Moderna Inc   46.34 %

Date modified: 2026-09-08T15:22:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.